[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 27 of about 27
1. Froehner M, Gaertner HJ, Manseck A, Oehlschlaeger S, Wirth MP: Retroperitoneal Leiomyosarcoma Associated with an Elevated beta-HCG Serum Level Mimicking Extragonadal Germ Cell Tumor. Sarcoma; 2000;4(4):179-81

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retroperitoneal Leiomyosarcoma Associated with an Elevated beta-HCG Serum Level Mimicking Extragonadal Germ Cell Tumor.
  • Patient. A 65-year-old man was admitted with a large primary retroperitoneal tumor and an increased beta-human chorionic gonadotropin (beta-HCG) serum level.
  • A germ cell tumor was suspected; however, a computed tomography-guided biopsy failed to enable tumor classification.
  • After two courses of chemotherapy, the beta-HCG serum level had returned to the normal level and a diagnostic laparotomy with incisional biopsy was performed.
  • The immunohistochemical examination of the specimen identified the tumor as a retroperitoneal pleomorphic leiomyosarcoma.Discussion.
  • Tumor markers play only a marginal role in the work-up of patients with soft tissue sarcomas.
  • In men with suspected retroperitoneal sarcomas, however, the determination of germ cell tumor markers occasionally enables a preoperative distinguishing of primary retroperitoneal germ cell tumors with considerable consequences for management.
  • In this setting, a retroperitoneal tumor associated with a moderately elevated beta-HCG is a diagnostic dilemma, and surgeons should be aware of the pitfall of a beta-HCG-producing leiomyosarcoma in the differential diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18521299.001).
  • [ISSN] 1357-714X
  • [Journal-full-title] Sarcoma
  • [ISO-abbreviation] Sarcoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2395440
  •  go-up   go-down


2. Kwon TW, Sung KB, Cho YP, Kim DK, Yang SM, Ro JY, Kim GE: Pararenal leiomyosarcoma of the inferior vena cava. J Korean Med Sci; 2003 Jun;18(3):355-9
Genetic Alliance. consumer health - Leiomyosarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pararenal leiomyosarcoma of the inferior vena cava.
  • A complete surgical resection is the only proven therapeutic modality that prolongs the survival in patients with leiomyosarcoma of the inferior vena cava (IVC).
  • Controversy exists in postoperative adjuvant therapy.
  • Recently, we experienced four cases of pararenal leiomyosarcoma of the IVC, of which treatment consisted of a complete resection of the tumor, ringed polytetrafluoroethylene (PTFE) graft interposition, and bilateral renal vein reconstructions in all patients.
  • Postoperative radiation therapy was instituted in 3 of 4 patients.
  • One patient who did not receive the postoperative radiation therapy was treated with adjuvant chemotherapy.
  • The kidneys were preserved in all patients and no deep vein thrombosis (DVT) or venous insufficiency of the lower extremity veins developed.
  • Distant metastasis to the lung was noted in one patient at 18 months after surgery, who was not received the postoperative radiation therapy but chemotherapy.
  • In conclusion, a complete resection of the tumor, IVC reconstruction, and bilateral renal vein reconstruction followed by adjuvant radiation therapy is recommended for the treatment of pararenal leiomyosarcoma of the IVC.
  • [MeSH-major] Leiomyosarcoma / radiotherapy. Leiomyosarcoma / surgery. Vascular Neoplasms / radiotherapy. Vascular Neoplasms / surgery. Vena Cava, Inferior
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Humans. Middle Aged. Neoplasm Recurrence, Local / radiography. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Recurrence, Local / surgery. Retroperitoneal Neoplasms / radiography. Retroperitoneal Neoplasms / radiotherapy. Retroperitoneal Neoplasms / surgery. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12808321.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC3055040
  •  go-up   go-down


3. Shirotake S, Sumitomo M, Asakuma J, Asano T, Aiko S, Hayakawa M: [A case of primary leiomyosarcoma of the ureter]. Hinyokika Kiyo; 2006 Jan;52(1):41-5
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of primary leiomyosarcoma of the ureter].
  • Retrograde pyelography, computed tomographic scan, and magnetic resonance imaging demonstrated left hydronephrosis due to a 7 cm retroperitoneal mass involving the left ureter.
  • Left nephroureterectomy and partial resection of the mesentery revealed a primary ureteral leiomyosarcoma.
  • Three months postoperatively, the patient received systemic chemotherapy (CYVADIC; cyclophosphamide, vincristine, adriamycin and DTIC) for a recurrent tumor.
  • Two courses of chemotherapy reduced the tumor by nearly 60%.
  • However, the tumor continued to progress and the patient died approximately one year after diagnosis.
  • [MeSH-major] Leiomyosarcoma / diagnosis. Ureteral Neoplasms / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Dacarbazine / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Magnetic Resonance Imaging. Middle Aged. Tomography, X-Ray Computed. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16479989.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; CYVADIC protocol
  •  go-up   go-down


Advertisement
4. Bay JO, Ray-Coquard I, Fayette J, Leyvraz S, Cherix S, Piperno-Neumann S, Chevreau C, Isambert N, Brain E, Emile G, Le Cesne A, Cioffi A, Kwiatkowski F, Coindre JM, Bui NB, Peyrade F, Penel N, Blay JY, Groupe Sarcome Français: Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis. Int J Cancer; 2006 Aug 1;119(3):706-11
Hazardous Substances Data Bank. DOCETAXEL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis.
  • Advanced soft-tissue sarcomas are usually resistant to cytotoxic agents such as doxorubicin and ifosfamide.
  • We conducted a retrospective study on 133 patients (58 males/75 females) with unresectable or metastatic soft-tissue sarcoma.
  • The median age at diagnosis was 51.7 (18-82), with 76 patients with leiomoyosarcoma and 57 patients with other histological subtypes.
  • The initial localizations were limb (44), uterine (32), retroperitoneal (23) and organs or bone (34).
  • No difference was found between uterine soft-tissue sarcomas versus others.
  • Better overall survival was correlated with leiomyosarcoma (p=0.01) and with the quality of the response, even for patients with stable disease (p<10(-4)).
  • Response to treatment and overall survival were better for patients in World Health Organization (WHO) performance status classification (PS) 0 at baseline versus patients in WHO PS-1, 2 or 3 (p=0.023 and p<10(-4), respectively).
  • Gemcitabine/docetaxel combination was tolerable and demonstrated better response and survival for leiomyosarcoma, especially for patients in WHO PS-0 at baseline.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Sarcoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Analysis of Variance. Deoxycytidine / administration & dosage. Deoxycytidine / adverse effects. Deoxycytidine / analogs & derivatives. Diarrhea / chemically induced. Drug Administration Schedule. Female. Humans. Leiomyosarcoma / drug therapy. Leiomyosarcoma / pathology. Male. Middle Aged. Nausea / chemically induced. Neutropenia / chemically induced. Retrospective Studies. Survival Analysis. Taxoids / administration & dosage. Taxoids / adverse effects. Thrombocytopenia / chemically induced. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 Wiley-Liss, Inc.
  • [ErratumIn] Int J Cancer. 2007 Jan 15;120(2):450. Penel, Nicolas [added]
  • (PMID = 16496406.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


5. Ulker V, Gungorduk K, Numanoglu C, Sahbaz A, Aslan O, Tekirdag AI, Gulkilik A: Complete surgical resection of retroperitoneal leiomyosarcoma in pregnancy: a case report. Arch Gynecol Obstet; 2008 Apr;277(4):353-6
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete surgical resection of retroperitoneal leiomyosarcoma in pregnancy: a case report.
  • Retroperitoneal soft tissue sarcoma (RPS) is extremely rare in pregnancy, so there has been little experience in dialing with this condition.
  • We report our experience of a pregnant patient with a retroperitoneal soft tissue sarcoma, which was treated by complete surgical resection at 17 weeks gestation.
  • Adjuvant radiotherapy and chemotherapy is controversial in RPS and due to postoperative continuation of pregnancy in our case, the adjuvant therapy was not practiced.
  • [MeSH-major] Leiomyosarcoma / surgery. Pregnancy Complications, Neoplastic / surgery. Retroperitoneal Neoplasms / surgery. Soft Tissue Neoplasms / surgery

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • Genetic Alliance. consumer health - Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17851674.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


6. Giménez de Marco B, Berné Manero JM, Bono Ariño A, Marigil Gómez MA, Esclarín Duny MA, Sanz Velez JI: [Retroperitoneal leiomyosarcoma]. Actas Urol Esp; 2001 Jul-Aug;25(7):523-6
Genetic Alliance. consumer health - Leiomyosarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Retroperitoneal leiomyosarcoma].
  • [Transliterated title] Leiomiosarcoma retroperitoneal.
  • We report a case of retroperitoneal leiomyosarcoma recurrence.
  • This entity is rare, < 0.2% of all tumours in humans and 25-30% of retroperitoneal sarcomas.
  • The diagnosis is usually delayed in relationship with scarce clinical signs which favorite the development of great tumour volume before diagnosis.
  • The treatment is surgical, with wide margins excision.
  • Radiotherapy and chemotherapy are not adequates for treatment of this pathological entity.
  • [MeSH-major] Leiomyosarcoma / diagnosis. Retroperitoneal Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11534408.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas espanolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


7. Mansi IA, Ashley I, Glezerov V: Retroperitoneal leiomyosarcoma and enlarged epididymis associated with a positive pregnancy test. Am J Med Sci; 2002 Aug;324(2):104-5
Genetic Alliance. consumer health - Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retroperitoneal leiomyosarcoma and enlarged epididymis associated with a positive pregnancy test.
  • Computerized tomography of the abdomen revealed a retroperitoneal mass measuring 30 x 21 x 13 cm.
  • Results of histopathology tests confirmed the diagnosis of leiomyosarcoma.
  • The level of serum beta-HCG decreased to < 0.2 mlU/mL after chemotherapy.
  • [MeSH-major] Biomarkers, Tumor / secretion. Chorionic Gonadotropin, beta Subunit, Human / secretion. Epididymis / pathology. Leiomyosarcoma / diagnosis. Leiomyosarcoma / secretion. Retroperitoneal Neoplasms / diagnosis. Retroperitoneal Neoplasms / secretion

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12186103.001).
  • [ISSN] 0002-9629
  • [Journal-full-title] The American journal of the medical sciences
  • [ISO-abbreviation] Am. J. Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chorionic Gonadotropin, beta Subunit, Human
  •  go-up   go-down


8. Okuno S, Edmonson J, Mahoney M, Buckner JC, Frytak S, Galanis E: Phase II trial of gemcitabine in advanced sarcomas. Cancer; 2002 Jun 15;94(12):3225-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The authors evaluated gemcitabine in patients with histologically confirmed sarcomas; one prior exposure to chemotherapy treatment was allowed.
  • Treatment consisted of gemcitabine 1250 mg/m(2) intravenously over 30 minutes, every week x three, cycles repeated q28 days.
  • RESULTS: Twenty nine of 30 patients were evaluable; one patient refused to initiate study treatment.
  • Patients were histologically classified as leiomyosarcoma (seven gastrointestinal, four retroperitoneal, two inferior vena caval, three of the extremity, and two uterine), synovial (two patients), malignant fibrous histiocytoma (two patients), fibrosarcoma (one patient), osteosarcoma (two patients), liposarcoma (one patient), hemangiosarcoma (one patient), or giant cell (one patient).
  • Eighty three percent of patients discontinued treatment due to progression and 14% due to toxicity/refusal.
  • One partial response was observed in a uterine leiomyosarcoma patient lasting at least three months.
  • Median time -to progression was 2.1 months (95% CI: 1.8-3.0).
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Sarcoma / drug therapy

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 American Cancer Society.
  • (PMID = 12115355.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


9. Sokolich J, Mejia A, Cheng S, Dunn E: Retroperitoneal leiomyosarcoma of the inferior vena cava mimicking a liver tumor. Am Surg; 2008 May;74(5):433-6
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retroperitoneal leiomyosarcoma of the inferior vena cava mimicking a liver tumor.
  • Leiomyosarcoma of the inferior vena cava (IVC) is a rare sarcoma, but it is the most common primary malignancy of the IVC.
  • Initial work-up including sonography, computed tomography, and magnetic resonance showed a tumor in the right upper quadrant of the abdominal cavity originating from the liver with compression of the IVC and displacement of the right kidney.
  • Postoperatively, she was placed on Coumadin and adjuvant chemotherapy was started.
  • Subsequently, the patient developed metastasis into the liver and peripancreatic nodes during the follow-up period.
  • [MeSH-major] Leiomyosarcoma / diagnosis. Liver Neoplasms / diagnosis. Retroperitoneal Neoplasms / diagnosis. Vascular Neoplasms / diagnosis. Vena Cava, Inferior / pathology
  • [MeSH-minor] Biopsy. Blood Vessel Prosthesis Implantation. Chemotherapy, Adjuvant. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Laparotomy. Lymphatic Metastasis / pathology. Middle Aged

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18481503.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Perera GB, Wilson SE, Barie PS, Butler JA: Duodenocaval fistula: a late complication of retroperitoneal irradiation and vena cava replacement. Ann Vasc Surg; 2004 Jan;18(1):52-8
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Duodenocaval fistula: a late complication of retroperitoneal irradiation and vena cava replacement.
  • Although migrating or ingested foreign bodies, trauma, and peptic ulcer disease are often described etiologies, 11 patients have been described who developed DCF after resection of retroperitoneal tumors, 9 of whom also had postoperative radiotherapy.
  • We report two patients who developed DCF after resection of retroperitoneal tumors followed by radiation therapy.
  • The first patient, a 56-year-old female, presented with upper gastrointestinal hemorrhage requiring transfusion caused by a duodenoprosthetic caval fistula 7 years after successful resection of a retroperitoneal leiomyosarcoma and replacement of the inferior vena cava followed by radiation and chemotherapy.
  • The second patient, a 37-year-old male who had previously undergone resection of a retroperitoneal sarcoma followed by external radiotherapy, developed massive upper and lower gastrointestinal bleeding secondary to a duodenocaval fistula.
  • The etiology, diagnosis, and treatment of DCF are analyzed with an emphasis on DCF following resection and irradiation of retroperitoneal tumors.
  • In most patients, "spontaneous" DCF have occurred as a late complication of high-dose radiation for carcinoma of the right kidney or retroperitoneal structures.
  • [MeSH-major] Aortic Diseases / etiology. Duodenal Diseases / etiology. Intestinal Fistula / etiology. Radiotherapy, Adjuvant / adverse effects. Retroperitoneal Neoplasms / radiotherapy. Sarcoma / radiotherapy. Vascular Fistula / etiology. Vena Cava, Inferior

  • MedlinePlus Health Information. consumer health - Small Intestine Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14727160.001).
  • [ISSN] 0890-5096
  • [Journal-full-title] Annals of vascular surgery
  • [ISO-abbreviation] Ann Vasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 40
  •  go-up   go-down


11. Leu KM, Ostruszka LJ, Shewach D, Zalupski M, Sondak V, Biermann JS, Lee JS, Couwlier C, Palazzolo K, Baker LH: Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. J Clin Oncol; 2004 May 1;22(9):1706-12
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma.
  • PURPOSE: A recent report of the combination of gemcitabine and docetaxel described favorable results in patients with uterine leiomyosarcoma.
  • Additionally, cell-culture studies were performed to assess the effect of the sequence of drug administration on colony formation.
  • Responses occurred in uterine, extremity, and retroperitoneal leiomyosarcoma, osteosarcomas, angiosarcomas, malignant fibrous histiocytomas, malignant peripheral-nerve sheath tumors, and Ewing's sarcoma.
  • In contrast, the administration of drugs simultaneously resulted in antagonism, and docetaxel followed by gemcitabine provided mixed results.
  • A multicenter, randomized clinical trial in soft tissue sarcoma comparing gemcitabine alone with this combination, is ongoing.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Deoxycytidine / analogs & derivatives. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy. Taxoids / therapeutic use
  • [MeSH-minor] Adult. Aged. Drug Administration Schedule. Drug Interactions. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15117993.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


12. Canales BK, Lukasewycz SJ, Manivel JC, Pryor JL: Postradiotherapy intratesticular leiomyosarcoma. Urology; 2005 Sep;66(3):657
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postradiotherapy intratesticular leiomyosarcoma.
  • We report what we believe to be the first case of high-grade, radiation-induced, intratesticular leiomyosarcoma in a 30-year-old man who had had testicular relapse of acute lymphoblastic leukemia at age 12 years that was treated with standard testicular field radiation (2400 cGy) and chemotherapy.
  • Radiation-induced tumors of this type are rare, have a median latency of 10 years, and are usually dose dependent (around 5000 cGy).
  • Testicular leiomyosarcoma, especially high grade, remains to be fully characterized.
  • The use of retroperitoneal lymph node dissection and chemotherapy remains controversial but is probably not indicated.
  • [MeSH-major] Leiomyosarcoma / etiology. Neoplasms, Radiation-Induced. Testicular Neoplasms / etiology

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16140103.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 12
  •  go-up   go-down


13. Perez EA, Gutierrez JC, Moffat FL Jr, Franceschi D, Livingstone AS, Spector SA, Levi JU, Sleeman D, Koniaris LG: Retroperitoneal and truncal sarcomas: prognosis depends upon type not location. Ann Surg Oncol; 2007 Mar;14(3):1114-22
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retroperitoneal and truncal sarcomas: prognosis depends upon type not location.
  • BACKGROUND: Prognostication of truncal and retroperitoneal soft tissue sarcomas has traditionally been predicated on tumor location and grade.
  • OBJECTIVE: To compare outcomes for patients with retroperitoneal or truncal sarcomas.
  • The most common tumor types were liposarcoma (35.9%), leiomyosarcoma (30.1%), and malignant fibrous histiocytoma (MFH) (19.5%).
  • Tumor distributions were retroperitoneal (38.9%), pelvic (24.7%), abdominal (18.6%) and thoracic (17.9%).
  • Univariate analysis comparing retroperitoneal versus truncal location demonstrated no significant differences in survival.
  • Multivariate analysis of pre-treatment variables showed increasing age, grade, histopathology (leiomyosarcoma and MFH) and metastasis to be associated with worse outcomes.
  • Multivariate analysis of the treatment variables showed that surgery and negative resection margins were associated with improved survival (P < 0.001).
  • CONCLUSIONS: Successful operative resection can confer prolonged disease-free survival and cure for truncal and retroperitoneal sarcomas.
  • Future studies should focus on histological subtype rather than tumor location for truncal and retroperitoneal sarcomas.
  • [MeSH-major] Retroperitoneal Neoplasms / pathology. Sarcoma / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Extremities / pathology. Female. Fibrosarcoma / drug therapy. Fibrosarcoma / pathology. Fibrosarcoma / surgery. Histiocytoma, Benign Fibrous / drug therapy. Histiocytoma, Benign Fibrous / pathology. Histiocytoma, Benign Fibrous / surgery. Humans. Leiomyosarcoma / drug therapy. Leiomyosarcoma / pathology. Leiomyosarcoma / surgery. Liposarcoma / drug therapy. Liposarcoma / pathology. Liposarcoma / surgery. Male. Middle Aged. Prognosis. Retrospective Studies. Risk Factors. Survival Rate. Time Factors

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17206483.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Murakami M, Tsukada H, Ikeda M, Watanabe M, Muramatsu T, Miyamoto T, Makino T, Yasuda S, Ide M, Nasu S: Availability of whole-body positron emission tomography (PET) for the detection of metastatic sites in recurrent uterine sarcoma. J Clin Oncol; 2004 Jul 15;22(14_suppl):5100

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Availability of whole-body positron emission tomography (PET) for the detection of metastatic sites in recurrent uterine sarcoma.
  • Accurate diagnosis of the metastatic sites is important for the treatment strategy.
  • Unfortunately current diagnostic techniques, including CT, MRI, and ultrasonography (US) are not efficient for the detection of recurrence.
  • There is little report of the experience with whole-body 18 fluorodeoxyglucose (FDG)-PET for the detection of recurrence in the follow up of patients with uterine sarcomas.
  • The purpose of this study is to evaluate the availability of FDG-PET for the detection of recurrence in patients with uterine sarcomas.
  • METHODS: Twelve patients with pathologically proven uterine sarcomas (nine leiomyosarcoma and three carcinosarcoma) took FDG-PET, CT, MRI and US for the purpose of the detection of recurrence after the primary treatment.
  • RESULTS: The final diagnoses of recurrence were established in five cases (three carcinosarcoma and two leiomyosarcoma).
  • PET scan showed all recurrent sites of intraperitoneum, liver, lung and retroperitoneal lymph nodes.
  • Positive results of PET scan did not affect the prognosis in four patients, but another patient with solitary intraperitoneal tumor by PET scan could received the chemotherapy and operation, which histologically confirmed the recurrence of leiomyosarcoma.
  • CONCLUSIONS: Whole-body FDG-PET had high sensitivity for detecting both intraperitoneal and/or retroperitoneal metastases.
  • Application of PET scan for the early detection of recurrence may affect the prognosis of some patients with uterine sarcoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015696.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Rosser CJ, Slaton JW, Izawa JI, Levy LB, Dinney CP: Clinical presentation and outcome of high-grade urinary bladder leiomyosarcoma in adults. Urology; 2003 Jun;61(6):1151-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical presentation and outcome of high-grade urinary bladder leiomyosarcoma in adults.
  • OBJECTIVES: To determine the clinical presentation and outcome of patients with high-grade bladder leiomyosarcoma.
  • METHODS: Between July 1986 and April 1998, 36 adult patients (mean follow-up 56 months) with a diagnosis of urinary bladder leiomyosarcoma were evaluated at the University of Texas M. D.
  • We retrospectively reviewed the records of these patients for information on clinical features, treatment, and outcome.
  • Thirty-five patients were treated surgically for bladder leiomyosarcoma; of these, 12 (34%) developed recurrent disease (5 with local recurrence and 7 with distant metastasis), with a median time to diagnosis of recurrent disease of 8.3 months.
  • The most common site of distant failure was the retroperitoneum.
  • Multivariate analyses demonstrated that only the Memorial Sloan-Kettering Cancer Center disease stage system was a significant predictor of survival of patients with bladder leiomyosarcoma (P = 0.018).
  • CONCLUSIONS: In patients with high-grade leiomyosarcoma of the bladder, radical cystectomy in the face of localized disease, whether at the initial presentation or after neoadjuvant chemotherapy, can result in a 5-year, disease-specific survival rate of 62.0%.
  • [MeSH-major] Leiomyosarcoma / diagnosis. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant / methods. Cystectomy / methods. Female. Follow-Up Studies. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local / diagnosis. Retroperitoneal Neoplasms / secondary. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Urology. 2004 Jul;64(1):188 [15245972.001]
  • (PMID = 12809885.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA16672
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


16. Labanaris AP, Zugor V, Smiszek R, Nützel R, Kühn R: Primary leiomyosarcoma of the testis. A case report. Anticancer Res; 2010 May;30(5):1725-6
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary leiomyosarcoma of the testis. A case report.
  • Primary leiomyosarcoma of the testis is an extremely rare disease entity of the genito-urinary tract.
  • Diagnosis is achieved by combining histologic and immunohistochemical findings.
  • Although the number of reported cases is not significant and the clinical and biological behaviour of these tumors are very hard to predict, we demonstrate that radical orchidectomy followed by surveillance appears to be the treatment of choice.
  • Retroperitoneal lymphadenectomy, radiotherapy and chemotherapy do not seem to have any place in the treatment of this type of malignancy.
  • [MeSH-major] Leiomyosarcoma / diagnosis. Leiomyosarcoma / pathology. Testicular Neoplasms / diagnosis. Testicular Neoplasms / pathology

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20592368.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


17. Raut CP, Pisters PW: Retroperitoneal sarcomas: Combined-modality treatment approaches. J Surg Oncol; 2006 Jul 1;94(1):81-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retroperitoneal sarcomas: Combined-modality treatment approaches.
  • Retroperitoneal sarcomas (RPS) are rare tumors, accounting for approximately 15% of soft tissue sarcomas.
  • Investigators are evaluating combined-modality therapies to improve local control and disease-specific survival.
  • This review outlines current concepts and evolving treatment strategies in the diagnosis, staging, and management of RPS.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Retroperitoneal Neoplasms / surgery. Sarcoma / surgery
  • [MeSH-minor] Biopsy, Needle. Combined Modality Therapy. Drug Administration Schedule. Humans. Intraoperative Care. Leiomyosarcoma / radiotherapy. Magnetic Resonance Imaging. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Preoperative Care. Prognosis. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16788949.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 30
  •  go-up   go-down


18. Kyriazi MA, Stafyla VK, Chatzinikolaou I, Koureas A, Chatziioannou A, Kondi-Paphiti A, Arkadopoulos N, Smyrniotis V: Surgical challenges in the treatment of leiomyosarcoma of the inferior vena cava: analysis of two cases and brief review of the literature. Ann Vasc Surg; 2010 Aug;24(6):826.e13-7
Genetic Alliance. consumer health - Leiomyosarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical challenges in the treatment of leiomyosarcoma of the inferior vena cava: analysis of two cases and brief review of the literature.
  • BACKGROUND: Leiomyosarcoma of the inferior vena cava (IVC) is a rare tumor of mesenchymal origin.
  • Optimal treatment should include complete resection of the malignant lesion with preservation of venous return.
  • METHODS AND RESULTS: The first case is that of a 54-year-old woman, with a 9 cm a primary IVC leiomyosarcoma extending from the level of the right renal vein to the common iliac veins.
  • She received adjuvant chemotherapy and is free of recurrence almost 3 years after surgery.
  • The second case is that of a 56-year-old woman presenting with back pain due to an 8-cm retroperitoneal mass in close proximity to the right renal vein.
  • Pathological examination confirmed primary leiomyosarcoma of the IVC.
  • She received adjuvant chemotherapy, but was referred to our hospital with local recurrence 6 months after the operation and is suffering from disseminated abdominal disease almost a year postsurgery.
  • CONCLUSION: Radical surgical en bloc resection is the mainstay of treatment for IVC leiomyosarcomas.
  • [MeSH-major] Leiomyosarcoma / surgery. Vascular Neoplasms / surgery. Vascular Surgical Procedures. Vena Cava, Inferior / surgery
  • [MeSH-minor] Abdominal Pain / etiology. Back Pain / etiology. Chemotherapy, Adjuvant. Female. Humans. Magnetic Resonance Imaging. Middle Aged. Neoplasm Recurrence, Local. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Annals of Vascular Surgery Inc. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20471215.001).
  • [ISSN] 1615-5947
  • [Journal-full-title] Annals of vascular surgery
  • [ISO-abbreviation] Ann Vasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


19. Stoeckle E, Coindre JM, Bonvalot S, Kantor G, Terrier P, Bonichon F, Nguyen Bui B, French Federation of Cancer Centers Sarcoma Group: Prognostic factors in retroperitoneal sarcoma: a multivariate analysis of a series of 165 patients of the French Cancer Center Federation Sarcoma Group. Cancer; 2001 Jul 15;92(2):359-68
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in retroperitoneal sarcoma: a multivariate analysis of a series of 165 patients of the French Cancer Center Federation Sarcoma Group.
  • BACKGROUND: Surgery is the main prognostic factor in retroperitoneal sarcoma.
  • However, despite progress, surgery alone is rarely curative, and analysis of the causes of failures and of other prognostic factors are warranted to ascertain treatment orientations.
  • METHODS: Data of patients treated from 1.80 to 12.94 for primary retroperitoneal sarcoma were extracted from the French Federation of Cancer Centers Sarcoma Group registry.
  • Liposarcoma, leiomyosarcoma, and malignant fibrous histiocytoma represented 66% of the tumors.
  • Multimodality treatment included surgery (150 patients), radiotherapy (92 patients), and chemotherapy (77 patients).
  • The main prognostic factors for survival were initial metastases and surgery, which represented the major treatment-linked factor.
  • CONCLUSIONS: Aggressive surgery remains mandatory in retroperitoneal sarcoma, but a randomized trial is needed to evaluate the place of radiotherapy for local control.
  • [MeSH-major] Neoplasm Recurrence, Local. Retroperitoneal Neoplasms / pathology. Sarcoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 American Cancer Society.
  • (PMID = 11466691.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


20. Baratti D, Pennacchioli E, Kusamura S, Fiore M, Balestra MR, Colombo C, Mingrone E, Gronchi A, Deraco M: Peritoneal sarcomatosis: is there a subset of patients who may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy? Ann Surg Oncol; 2010 Dec;17(12):3220-8
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peritoneal sarcomatosis: is there a subset of patients who may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy?
  • BACKGROUND: Unlike novel molecular-targeted therapies for metastatic gastrointestinal stromal tumors (GIST), conventional treatments for peritoneal sarcomatosis (PS) are mostly ineffective.
  • As with carcinomatosis of epithelial origin, a rationale base supports an aggressive locoregional treatment of PS, but the use of CRS and HIPEC in this setting is still controversial.
  • We assessed the outcome of clinically and pathologically homogeneous subsets of patients with PS uniformly treated by cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
  • PS originated from GIST (pre-imatinib era) in 8 patients, uterine leiomyosarcoma (ULS) in 11, retroperitoneal liposarcoma (RPLP) in 13, and other sarcoma in 5.
  • CONCLUSIONS: Overall, results of CRS and HIPEC did not compare favorably to those of conventional therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Cancer, Regional Perfusion. Hyperthermia, Induced. Leiomyosarcoma / therapy. Peritoneal Neoplasms / therapy. Uterine Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Doxorubicin / administration & dosage. Female. Humans. Liposarcoma / classification. Liposarcoma / pathology. Liposarcoma / therapy. Male. Middle Aged. Mitomycin / administration & dosage. Neoplasm Staging. Prospective Studies. Retroperitoneal Neoplasms / classification. Retroperitoneal Neoplasms / pathology. Retroperitoneal Neoplasms / therapy. Survival Rate. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Ann Surg Oncol. 2011 Dec;18 Suppl 3:S327. Alessanrdro, Gronchi [corrected to Gronchi, Alessandro]
  • (PMID = 20585874.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; Retroperitoneal liposarcoma
  •  go-up   go-down


21. Tepetes K, Tsamandas AC, Ravazoula P, Petsas T, Bonikos DS, Karavias DD: Survival for 5 years after repeat liver resections and multimodality treatment for metastatic intestinal leiomyosarcoma: report of a case. Surg Today; 2002;32(10):925-8
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival for 5 years after repeat liver resections and multimodality treatment for metastatic intestinal leiomyosarcoma: report of a case.
  • The liver is a common site of metastases from gastrointestinal or retroperitoneal leiomyosarcomas.
  • We report the case of a woman who has survived for 5 years since her first liver resection, during which time five more resections have been performed, in combination with systemic chemotherapy and radiofrequency ablation.
  • [MeSH-major] Hepatectomy. Jejunal Neoplasms / pathology. Leiomyosarcoma / secondary. Leiomyosarcoma / surgery. Liver Neoplasms / secondary. Liver Neoplasms / surgery

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12376797.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


22. Melichar B, Voboril Z, Nozicka J, Cerman J Jr, Melicharová K, Mergancová J, Filip S, Krajina A, Voboril R, Jandík P: Hepatic arterial infusion chemotherapy in sarcoma liver metastases: a report of 6 cases. Tumori; 2005 Jan-Feb;91(1):19-23
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic arterial infusion chemotherapy in sarcoma liver metastases: a report of 6 cases.
  • The experience with liver-directed therapies, eg hepatic arterial infusion, in these patients is limited.
  • METHODS: Six patients with sarcoma metastatic to the liver (4 patients with gastrointestinal stromal tumors and 2 patients with leiomyosarcoma) were treated by hepatic arterial infusion in our center over a 12-year period.
  • RESULTS: None of the 5 assessable patients responded to the therapy, and liver metastases progressed in all patients.
  • CONCLUSIONS: Hepatic arterial infusion has little efficacy in the treatment of sarcoma metastatic to the liver.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Hepatic Artery. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Sarcoma / drug therapy. Sarcoma / secondary
  • [MeSH-minor] Adult. Aged. Female. Humans. Infusions, Intra-Arterial. Jejunal Neoplasms / pathology. Male. Middle Aged. Rectal Neoplasms / pathology. Retroperitoneal Neoplasms / pathology. Retrospective Studies. Stomach Neoplasms / pathology. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15850000.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Rossi CR, Casali P, Kusamura S, Baratti D, Deraco M: The consensus statement on the locoregional treatment of abdominal sarcomatosis. J Surg Oncol; 2008 Sep 15;98(4):291-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The consensus statement on the locoregional treatment of abdominal sarcomatosis.
  • Abdominal sarcomatosis (AS) is a rare condition characterized by soft tissue sarcoma spreading throughout the abdomen, in the absence of extra-abdominal dissemination.
  • Retroperitoneal sarcomas, pelvic sarcomas, particularly uterine leiomyosarcoma, and gastrointestinal stromal tumors (GISTs) most frequently give rise to AS.
  • Systemic chemotherapy is the standard of care for AS from non-GIST sarcomas, but with an essentially palliative aim and major limitations.
  • Innovative targeted therapies has deeply affected the natural history of GIST, at least in prolonging significantly survival in responsive patients.
  • In this context, the notion that abdominal spread in the lack of extra-peritoneal lesions may typically occur in a number of patients, along with the dismal prognosis generally carried by AS, has prompted a few centers to perform cytoreductive surgery and perioperative intraperitoneal chemotherapy.
  • To date, the rarity of these presentations makes it difficult to evaluate the clinical results and the role of combined local-regional treatment is still a matter of debate.
  • [MeSH-major] Abdominal Neoplasms / drug therapy. Abdominal Neoplasms / surgery. Chemotherapy, Cancer, Regional Perfusion / methods. Hyperthermia, Induced. Sarcoma / drug therapy. Sarcoma / surgery
  • [MeSH-minor] Chemotherapy, Adjuvant. Consensus. Humans. Infusions, Parenteral. Practice Guidelines as Topic

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18726899.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 24
  •  go-up   go-down


24. Murakami M, Tsukada H, Shida M, Watanabe M, Maeda H, Koido S, Hirasawa T, Muramatsu T, Miyamoto T, Nasu S, Yasuda S, Kajiwara H, Yasuda M, Ide M: Whole-body positron emission tomography with F-18 fluorodeoxyglucose for the detection of recurrence in uterine sarcomas. Int J Gynecol Cancer; 2006 Mar-Apr;16(2):854-60
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Whole-body positron emission tomography with F-18 fluorodeoxyglucose for the detection of recurrence in uterine sarcomas.
  • We evaluated the usefulness of whole-body positron emission tomography (PET) using F-18 fluorodeoxyglucose (FDG-PET) for the detection of recurrence in follow-up patients after primary treatment of uterine sarcoma.
  • Eight patients with pathologically proven uterine sarcoma underwent FDG-PET, computed tomography (CT), and ultrasonography (US).
  • PET revealed recurrent sites in the intraperitoneum, liver, lung, bone, and retroperitoneal lymph nodes.
  • Positive PET findings did not affect the prognosis in three of the five recurrent patients; however, the remaining two patients consequently underwent the combination therapy consisting of surgery and chemotherapy and survived for more than 1 year after the positive FDG-PET results.
  • Application of PET imaging for the early detection of recurrent sites was useful for the decision of treatment strategy for patients with recurrent uterine sarcoma.
  • [MeSH-major] Carcinosarcoma / radionuclide imaging. Fluorodeoxyglucose F18. Leiomyosarcoma / radionuclide imaging. Neoplasm Recurrence, Local / radionuclide imaging. Radiopharmaceuticals. Tomography, Emission-Computed. Uterine Neoplasms / radionuclide imaging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16681773.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


25. Méndez R, Arnáiz S, Montero M, Tellado M, País E, Ríos J, Vela D: [Clinical patterns of soft-tissue sarcoma in children]. Cir Pediatr; 2001 Jan;14(1):14-20
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical patterns of soft-tissue sarcoma in children].
  • INTRODUCTION AND OBJECTIVES: Soft tissue sarcomas are rare mesenchymal neoplasms that constitute less than 10% of all pediatric malignancies.
  • Half of these are rhabdomyosarcomas, the remaining 50% have a varied and heterogenous histologic and clinical patterns (fibrosarcoma, synovial cell sarcoma, extraskeletal Ewing's sarcoma, angiosarcoma, liposarcoma, leiomyosarcoma, ...).
  • The purpose of this work is to evaluate our clinical experience with soft tissue sarcomas in uncommon sites over the past 10 years in order to delimitate the prognostic factors in survival and modalities of treatment.
  • MATERIAL AND METHODS: Between 1989 and 1998, 10 patients were diagnosed with soft tissue sarcomas in uncommon sites and treated by us over a total number of 139 pediatric neoplasms (7.19%).
  • Variables investigated included histologic findings, tumor size, age at presentation, primary site, clinical group, radiologic test performed, surgical treatment, radiotherapy and adjuvant chemotherapy, complications and survival rates.
  • RESULTS: The following histologic types of these 10 tumors were identified: 1 hemangiopericytoma in oral cavity, 2 extraosseous Ewing's sarcoma, 1 botryoid rhabdomyosarcoma of the bladder, 1 mediastinal fibrosarcoma, 1 retroperitoneal rhabdomyosarcoma, 1 paratesticular rhabdomyosarcoma, 1 cervical condrosarcoma, 1 alveolar rhabdomyosarcoma and 1 deltoid rhabdomyosarcoma.
  • The mean age at diagnosis was 7 years (4.6 years accounted for rhabdomyosarcoma alone).
  • Adjuvant chemotherapy with IVA was followed by radiotherapy only in four patients.
  • All the children classified in clinical groups II, III or IV needed 2nd. line regimens of chemotherapy.
  • Three patients died in the follow-up instead of the multimodal treatment.
  • 2) radiotherapy will only be necessary if margins of resection cannot control the local disease, and 3) chemotherapy have not clearly demonstrated his benefits as adjuvant therapy in clinical group I lesions but his employ is recommended in all cases because of the poor prognosis due to local recurrence.
  • [MeSH-major] Sarcoma / therapy. Soft Tissue Neoplasms / therapy

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11339112.001).
  • [ISSN] 0214-1221
  • [Journal-full-title] Cirugía pediátrica : organo oficial de la Sociedad Española de Cirugía Pediátrica
  • [ISO-abbreviation] Cir Pediatr
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


26. Pawlik TM, Vauthey JN, Abdalla EK, Pollock RE, Ellis LM, Curley SA: Results of a single-center experience with resection and ablation for sarcoma metastatic to the liver. Arch Surg; 2006 Jun;141(6):537-43; discussion 543-4
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The primary sarcoma site was the abdomen or retroperitoneum (n = 22), stomach (n = 18), small or large bowel (n = 17), pelvis (n = 4), uterus (n = 3), or other (n = 2).
  • Tumor pathologic types included gastrointestinal stromal tumor (n = 36), leiomyosarcoma (n = 18), and sarcoma not otherwise classified (n = 12).
  • Treatment with radiofrequency ablation (either alone or combined with resection) (P = .002) and lack of adjuvant chemotherapy (P = .01) predicted shorter disease-free survival.
  • CONCLUSIONS: Long-term survival can be achieved following surgical treatment of sarcoma liver metastasis, especially in patients with gastrointestinal stromal tumor.
  • Patients with sarcoma liver metastasis should be evaluated by a multidisciplinary team, as recurrence is common and adjuvant therapy may prolong survival.
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Digestive System Neoplasms / pathology. Disease-Free Survival. Female. Gastrointestinal Stromal Tumors / pathology. Humans. Male. Middle Aged. Retroperitoneal Neoplasms / pathology. Retrospective Studies. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16785353.001).
  • [ISSN] 0004-0010
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


27. Malagón HD, Valdez AM, Moran CA, Suster S: Germ cell tumors with sarcomatous components: a clinicopathologic and immunohistochemical study of 46 cases. Am J Surg Pathol; 2007 Sep;31(9):1356-62
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Twenty-three tumors arose in the mediastinum, 2 in the retroperitoneum, and 21 in the gonads.
  • The SC included embryonal rhabdomyosarcoma (29), angiosarcoma (6), leiomyosarcoma (4), undifferentiated sarcoma (3), myxoid liposarcoma (1), malignant peripheral nerve sheath tumor (1), malignant "triton" tumor (1), and epithelioid hemangioendothelioma (1).
  • All patients were treated by cisplatinum-based chemotherapy plus other agents followed by surgery.
  • [MeSH-major] Immunohistochemistry. Mediastinal Neoplasms / diagnosis. Neoplasms, Germ Cell and Embryonal / diagnosis. Ovarian Neoplasms / diagnosis. Retroperitoneal Neoplasms / diagnosis. Sarcoma / diagnosis. Testicular Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Orchiectomy. Ovariectomy. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17721191.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement